Havrix (Hepatitis A Virus (Inactivated ) Adsorbed On Aluminium Hydroxide Hydrated Produced On Human Diploid)

Havrix is indicated for the prevention of hepatitis A virus infection in individuals who have not been previously immunized.

• Adults and children aged 12 months and older who require protection against hepatitis A.
• Travelers to regions where hepatitis A is endemic or where outbreaks have occurred.
• Persons at increased risk due to occupational exposure, such as laboratory workers handling hepatitis A virus.
• Individuals with chronic liver disease who need additional protection against hepatitis A complications.
• Outbreak control situations where rapid immunization of a population is recommended.

The safety profile of Havrix reflects the typical reactions observed with inactivated viral vaccines. These reactions are generally self‑limiting and do not require medical intervention.

Common

• Mild pain, redness, or swelling at the injection site.
• Low‑grade fever occurring within 24–48 hours after vaccination.
• Headache or fatigue that resolves spontaneously.
• Mild muscle aches or joint discomfort.
• Transient nausea or gastrointestinal discomfort.
• Mild rash or itching away from the injection site.
• Temporary dizziness or light‑headedness.
• Mild lymphadenopathy near the injection site.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Neurologic events including Guillain‑Barré syndrome, though reported rarely.
• Severe local reactions with extensive necrosis (extremely rare).
• Severe allergic reaction with respiratory compromise (rare).

Before receiving Havrix, certain health considerations should be reviewed to ensure safe administration.

• Confirm that the individual has not previously received a hepatitis A vaccine or documented immunity.
• Defer vaccination in persons with a known severe allergy to any vaccine component, including aluminium salts.
• Postpone administration in individuals experiencing an acute moderate or severe illness.
• Discuss pregnancy or breastfeeding status with a healthcare professional, as safety data are limited.
• Evaluate the presence of immunocompromising conditions that may affect vaccine response.
• Consider the timing of other vaccinations to avoid simultaneous administration unless advised.

Havrix may interact with other agents; awareness of potential interactions helps optimize vaccination timing.

Avoid

• Concurrent administration with live attenuated vaccines is generally avoided to prevent immune interference.
• Simultaneous receipt of immunoglobulin products that contain anti‑hepatitis A antibodies may reduce vaccine efficacy.

Use with caution

• Co‑administration with other inactivated vaccines (e.g., influenza, tetanus) is permissible but monitor for increased local reactions.
• Patients receiving immunosuppressive therapy may have a diminished immune response; timing of vaccination should be coordinated with the treating physician.
• Use caution when vaccinating individuals on high‑dose corticosteroids, as antibody production may be suboptimal.